// App-Quantinova.ai

75 : Cost effectiveness of a high intensity programme (HIP) compared to a low intensity programme (LIP) for switching patients with rheumatoid arthritis to the etanercept biosimilar

Researchers

Presenter

  • Kavina Shah

Principal Investigators

  • Kalveer Flora

  • Henry Penn

Medical Centers

  • N/A

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Regenerating Family Member 3 Alpha

Drug/Treatment

  • Etanercept biosimilar

  • Etanercept

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved